Business Wire

MobileIron Research Reveals 8 in 10 IT Leaders Want to Eliminate Passwords and Expect Mobile Devices to Become Primary Authentication to the Enterprise

Share

MobileIron (NASDAQ:MOBL) today revealed the results of a survey conducted with IDG, which found that enterprise users and security professionals alike are frustrated by the inefficiency and lax security of passwords for user authentication. With 90% of security professionals reporting to have seen unauthorized access attempts as a result of stolen credentials, it’s clear that the future of security requires a next generation of authentication that’s more secure.

Mobile devices are the best option for replacing passwords, as they remain at the center of enterprises in terms of where business is done, how access is given, and how authentication is done. In fact, the survey revealed that almost nine-in-ten (88%) security leaders believe that mobile devices will soon serve as digital ID to access enterprise services and data.

The survey, sponsored by MobileIron, polled 200 IT security leaders in the US, UK, Australia, and New Zealand working in a range of industries at companies with at least 500 employees. The aim was to discover the major authentication pain points facing enterprises.

“It’s time to say goodbye to passwords. They not only cause major frustrations for users and IT professionals, but they also pose major security risks,” said Rhonda Shantz, Chief Marketing Officer at MobileIron. “That’s why MobileIron is ushering in a new era of user authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. With more and more users accessing apps and company data via their own mobile devices, it’s not only easier to leverage mobile devices than passwords for user authentication – it’s also much more secure.”

The perils of passwords:

  • 90% of security pros have seen unauthorized access attempts as a result of stolen credentials.
  • Security leaders estimate that they could reduce their risk of breach by almost half by eliminating passwords.
  • Two out of every five (41%) of helpdesk tickets result from password or multi-factor authentication (MFA) lockout,
  • Password lockout sentiment for end-users: 68% feel disrupted; 63% feel irritated; 62% feel frustrated; 62% feel that they have wasted time.
  • Almost half (45%) of all end-users reuse personal and corporate passwords, which does not comport with security best-practices.
  • Security leaders estimate that they could reduce their risk of breach by almost half (43%) simply by eliminating passwords.
  • Almost every security leader (86%) would do away with passwords if they could.
  • Almost three-in-four (72%) security leaders are actively looking to replace passwords.

The merits of mobile:

  • Almost nine-in-ten (88%) security leaders believe that in the near future, mobile devices will serve as your digital ID to access enterprise services and data.
  • About two-in-five end-users (42%) need daily access to mobile business apps, but that number is expected to grow significantly in the next two years.
    • Almost all organizations saw the use of business apps expand last year (85%).
    • Almost all organizations expect to see continued expansion in the next 2 years (87%).
    • Millennials are driving demand for broader access to business apps on mobile devices (94% vs. 73% non-Millennials).

MobileIron recently introduced a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution. MobileIron’s platform allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password.

To download a complimentary copy of the IDG survey results, please visit here.

About MobileIron

MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Becca Chambers
Head of Global Corporate Communications
bchambers@mobileiron.com
650.722.1647

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye